Dear Spiral User, we appreciate your patience during this upgrade which is to benefit our userbase, improve their experience in Spiral, introduce improvements, fixes and maintaining our versioning for future updates. Please note if you encounter any issues in Spiral, please raise a ticket to Research Applications team providing as much detail as possible in order to help us resolve your query. Again, we thank you for your patience and support during the upgrade. Kind Regards, Spiral Upgrade Team.
 
National clinical expert consensus statement: Coronavirus monoclonal antibodies as a prophylactic therapy against COVID-19 for immunocompromised groups
File(s)
Author(s)
Mullish, Benjamin H
Type
Report
Abstract
- Novel long-acting coronavirus prophylactic monoclonal antibody
therapies have been shown to be effective in preventing COVID19 in immunocompromised individuals who are at increased risk
from SARS-CoV-2.
- Prophylactic antibody therapies should be made available in a
timely manner to give an antibody immunity boost to vulnerable
patients.
- Real world evaluations should be co-implemented to provide
confidence of ongoing effectiveness.
- Successful delivery of a coronavirus prophylactic antibody
therapy programme would deliver significant benefits to
healthcare systems, communities and immunocompromised
individuals.
Date Issued
2022-07-30
Citation
2022, pp.1-5
URI
URL
DOI
Start Page
1
End Page
5
Copyright Statement
© 2022 The Author(s).
Identifier
https://appg-vulnerablegroups.org/fileadmin/user_upload/Prophylactic_clinical_consensus_statement.pdf
Publication Status
Published